Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
212.31B
Market cap212.31B
Price-Earnings ratio
14.24
Price-Earnings ratio14.24
Dividend yield
2.51%
Dividend yield2.51%
Average volume
14.08M
Average volume14.08M
High today
$48.75
High today$48.75
Low today
$47.51
Low today$47.51
Open price
$48.09
Open price$48.09
Volume
10.34M
Volume10.34M
52 Week high
$109.04
52 Week high$109.04
52 Week low
$43.08
52 Week low$43.08

Stock Snapshot

Novo Nordisk(NVO) stock is priced at $47.64, giving the company a market capitalization of 212.31B. It carries a P/E multiple of 14.24 and pays a dividend yield of 2.5%.

As of 2025-12-17, Novo Nordisk(NVO) stock has fluctuated between $47.51 and $48.75. The current price stands at $47.64, placing the stock +0.3% above today's low and -2.3% off the high.

Novo Nordisk(NVO) shares are trading with a volume of 10.34M, against a daily average of 14.08M.

In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $109.04 and a 52-week low of $43.08.

In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $109.04 and a 52-week low of $43.08.

NVO News

TipRanks 9h
Novo Nordisk’s New Pediatric Weight Management Study: Key Updates for Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...

Simply Wall St 1d
Novo Nordisk: Reassessing Valuation After Recent Share Price Rebound and Prolonged Downtrend

Stock performance snapshot Novo Nordisk (NYSE:NVO) shares have quietly rebounded about 8% over the past week, trimming some of this year’s heavy slide. As a re...

Novo Nordisk: Reassessing Valuation After Recent Share Price Rebound and Prolonged Downtrend
Benzinga 2d
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro. Novo Nordisk’s stock was significantly hit when the compa...

Analyst ratings

55%

of 33 ratings
Buy
54.5%
Hold
30.3%
Sell
15.2%

More NVO News

Benzinga 2d
Why Is Novo Nordisk Stock Falling Tuesday? - Eli Lilly, Novo Nordisk - Benzinga

...

Why Is Novo Nordisk Stock Falling Tuesday? - Eli Lilly, Novo Nordisk - Benzinga
TipRanks 3d
Novo Nordisk’s New Study on Ziltivekimab: A Potential Game-Changer in Heart Attack Treatment

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...

TipRanks 3d
Novo Nordisk’s New Study on GLP-1 Medications: What Investors Need to Know

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...

TipRanks 3d
Novo Nordisk’s CagriSema Study: A Potential Game-Changer in Diabetes Management

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...

Simply Wall St 4d
Does The Recent Slide In Novo Nordisk Signal A Long Term Opportunity For Investors?

Wondering if Novo Nordisk is a bargain or a bubble at today’s price? You are not alone, and this breakdown will clarify what you are really paying for. After a...

Does The Recent Slide In Novo Nordisk Signal A Long Term Opportunity For Investors?
Nasdaq 5d
Warren Buffett Detailed Fundamental Analysis - NVO

Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...

Warren Buffett Detailed Fundamental Analysis - NVO
Benzinga 5d
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy

On Friday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk A/S’ (NYSE:NVO...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.